|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM356039633 |
| 003 |
DE-627 |
| 005 |
20231226065620.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109342
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1186.xml
|
| 035 |
|
|
|a (DE-627)NLM356039633
|
| 035 |
|
|
|a (NLM)37100338
|
| 035 |
|
|
|a (PII)S1521-6616(23)00121-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Shen, Ching-Fen
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.05.2023
|
| 500 |
|
|
|a Date Revised 23.05.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a BACKGROUND: Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination
|
| 520 |
|
|
|a METHODS: We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay
|
| 520 |
|
|
|a RESULTS: All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4+ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender
|
| 520 |
|
|
|a CONCLUSIONS: A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4+ T cells response correlates with post-booster neutralization reactivity against the Omicron variant
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Adenovirus vector vaccine
|
| 650 |
|
4 |
|a COVID-19 vaccines
|
| 650 |
|
4 |
|a Heterologous prime-boost immunization
|
| 650 |
|
4 |
|a Neutralizing antibody
|
| 650 |
|
4 |
|a T cell response
|
| 650 |
|
4 |
|a mRNA vaccine
|
| 650 |
|
7 |
|a 2019-nCoV Vaccine mRNA-1273
|2 NLM
|
| 650 |
|
7 |
|a EPK39PL4R4
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 700 |
1 |
|
|a Fu, Yi-Chen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ho, Tzong-Shiann
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Po-Lin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Nan-Yao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsai, Bo-Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsai, Pei-Jane
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ko, Wen-Chien
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Ching-Chuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Chao-Min
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shieh, Chi-Chang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 251(2023) vom: 01. Juni, Seite 109342
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:251
|g year:2023
|g day:01
|g month:06
|g pages:109342
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109342
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 251
|j 2023
|b 01
|c 06
|h 109342
|